Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 6245899
Composition for detection of cell density signal molecule
expired -
US 6241990
Immunogenic composition containing inactivated swine infertility and respiratory Syndrome virus
expired -
US 6242253
IkB kinase, subunits thereof, and methods of using same
expired -
US 6242418
Therapeutic uses of BPI protein products for human meningococcemia
expired -
US 6242488
Method for preventing and treating pain
expired -
US 6238861
Neurofibromatosis gene
expired -
US 6239104
Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
expired -
US 6239180
Transdermal therapeutic device and method with capsaicin and capsaicin analogs
expired -
US 6239258
Human Nkx-2.2 polypeptide-encoding nucleotide sequences
expired -
US 6235481
Polynucleotides encoding calpain 10
expired -
US 6235309
Inhibition of cell-cell binding by lipid assemblies
expired -
US 6235772
Lipoic acid analogs
expired -
US 6235881
Polypeptides encoded by novel HIV-2 proviruses
expired -
US 6232444
Conserved anti-DNA antibody idiotype associated with nephritis in murine and human lupus
expired -
US 6232119
Immortalized human fetal neuronal cell line
expired -
US 6231852
Method for reducing BCL-2 expressing cells resistance to death
expired -
US 6231892
Compositions for coating microcapsules and other surfaces
expired -
US 6228873
Method for enhancing outflow of aqueous humor in treatment of glaucoma
expired -
US 6228843
Method of using PKC inhibiting compounds to treat vascular disease
expired -
US 6225070
Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
expired -
US 6225456
Ras suppressor SUR-5
expired -
US 6225292
Inhibitors of DNA immunostimulatory sequence activity
expired -
US 6225290
Systemic gene therapy by intestinal cell transformation
expired -
US 6224893
Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering
expired -
US 6221877
Substituted 4-phthalimidocarboxanilides as inhibitors of purine salvage phosphoribosyltransferases
expired -
US 6221401
Bilayer structure which encapsulates multiple containment units and uses thereof
expired -
US 6221861
Reducing pyrophosphate deposition with calcium antagonists
expired -
US 6221856
Inositol derivatives for inhibiting superoxide anion production
expired -
US 6221910
Glutamine containing oral replacement solution
expired -
US 6217871
Antigenic epitopes with LYM-1 reactivity and uses thereof
expired -
US 6218372
Methods for treating restenosis with p21
expired -
US 6218526
Polynucleotide encoding human netrin-1
expired -
US 6218437
Treatment and prevention of hepatic disorders
expired -
US 6217864
Method for targeted degradation of intracellular proteins in vivo or ex vivo
expired -
US 6214388
Immunoliposomes that optimize internalization into target cells
expired -
US 6214562
Transcriptionally regualted G protein-coupled receptor
expired -
US 6214571
Method for inhibiting adenylosuccinate synthetase activity in malignant methylthioadenosine phosphorylase deficient cells
expired -
US 6214594
Size enhanced fibrinolytic enzymes: limitations of plasma inactivation
expired -
US 6214801
Imidazo[1,2-a]pyridine C-nucleosides as antiviral agents
expired -
US 6210918
Non-invasive method for detection, diagnosis or prediction of term or pre-term labor
expired -
US 6210873
Methods and compositions for the priming of specific cytotoxic T-lymphocyte response
expired -
US 6211355
Radionuclide labeling of vitamin B12 and coenzymes thereof
expired -
US 6210707
Methods of forming protein-linked lipidic microparticles, and compositions thereof
expired -
US 6210917
Method for suppressing multiple drug resistance in cancer cells
expired -
US 6211148
Antimicrobial peptides from bovine neutrophis
expired -
US 6207159
Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
expired -
US 6206931
Graft prosthesis materials
expired -
US 6207690
Troglitazone compounds for treating climacteric and cancer
expired
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory